Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
Objective: To analyze the total direct cost of anticoagulant therapies indicated for the chronic treatment of patients with non-valvular atrial fibrillation (AF) and the acute treatment of venous thromboembolism (VTE) in the perspective of a tertiary teaching hospital and the national public health...
Guardado en:
Autores principales: | Isabella C DENARDIN, Helena H. BORBA, Antonio M. MENDES |
---|---|
Formato: | article |
Lenguaje: | EN PT |
Publicado: |
Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/166e9290e0ee4250a16d5ef8c03ef9d5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Direct Oral Anticoagulant (DOAC) to Warfarin Transitions in a Pharmacist-led Anticoagulation Clinic
por: Ashley G. Woodhouse, et al.
Publicado: (2019) -
The Clinical Pharmacist assessment in the prophylaxis of venous thromboembolism in a university hospital
por: Julia S. GOMES, et al.
Publicado: (2021) -
Guest editorial: The ten most important qualities for the profession of medicinal research
por: Tony Y. Zhang
Publicado: (2021) -
Correction: Structural Racism and Supporting Black Lives – A Pharmacist’s Vow amid COVID-19
por: Nicole D. Avant
Publicado: (2021) -
An Overview of COVID-19 Vaccine Safety and Post-marketing Surveillance Systems
por: Manal Mohammed Younus, et al.
Publicado: (2021)